The FDA biQ-FEL recall now covers two specific 500 mL lots after laboratory testing found undeclared sildenafil and tadalafil. A&P Creations LLC announced the consumer-level recall on September 14, 2026, and FDA published it on September 15.
Consumers who have an affected bottle are told to stop using it immediately and destroy the product. The recall is a new action stage, but the underlying hazard is not new: FDA had already warned consumers on May 27, 2026 not to purchase or use biQ-FEL after its laboratory analysis found the same undeclared drug ingredients.
Which biQ-FEL 500 mL lots are recalled?
| Lot number | Expiration date printed by FDA |
|---|---|
| biQ-f001-06-25 | 05/06/27 |
| biQ-003-01-26 | 01/01/28 |
The second recalled lot is associated with barcode identifier 7709799120663 in the FDA-posted recall notice. Consumers should compare the bottle’s lot information carefully rather than relying only on the product name.
What should consumers do with recalled biQ-FEL?
The company recall notice posted by FDA tells consumers with recalled biQ-FEL 500 mL to stop using it immediately and urges them to destroy the product.
A&P Creations says it has stopped distributing biQ-FEL 500 mL and is notifying affected customers through direct electronic notifications and applicable marketplace customer-notification procedures.
If you experienced a problem that may be related to using the product, the recall notice directs consumers to contact a physician or healthcare provider. Adverse reactions or quality problems can also be reported through FDA’s MedWatch program.
Where was the recalled product sold?
The FDA-posted recall says the affected biQ-FEL 500 mL product was distributed to consumers in the United States through Amazon, Walmart.com and naturefuel.us.
The bottle carries the biQ-FEL name and includes Spanish-language label text, including the flavour wording identified in the recall notice. Distribution through online marketplaces means consumers who ordered previously should check their bottle rather than assuming the current marketplace listing state proves their earlier purchase was unaffected.
Why is biQ-FEL being recalled?
FDA laboratory analysis identified sildenafil and tadalafil in biQ-FEL even though those ingredients were not declared on the product label.
Sildenafil and tadalafil are active ingredients in FDA-approved prescription medicines used for erectile dysfunction. FDA warns that undeclared use is important because these ingredients can interact with nitrates, including medicines such as nitroglycerin, and may lower blood pressure to dangerous levels.
The recall notice notes that people with conditions such as diabetes, high blood pressure, high cholesterol or heart disease may take nitrates. TPS is not treating that list as proof that every person with one of those conditions is taking a nitrate; medication risk must be assessed from the individual’s actual medicines and health situation.
Was the hidden-drug problem first discovered in September?
No. FDA had already issued a public warning about biQ-FEL on May 27, 2026 after its laboratory analysis confirmed sildenafil and tadalafil that were not listed on the label.
The September development is therefore a recall and consumer-action escalation, not the first discovery of the hidden ingredients.
The lifecycle is:
- May 27: FDA warned consumers not to purchase or use biQ-FEL because laboratory testing found undeclared sildenafil and tadalafil.
- September 14: A&P Creations announced a consumer-level recall covering specified biQ-FEL 500 mL lots.
- September 15: FDA published the company’s recall announcement.
Were any adverse events reported?
According to the recall notice, A&P Creations had received no reports of adverse events related to this recall as of September 14, 2026.
That does not remove the reason for the recall or the FDA stop-use instruction. It only describes the adverse-event reporting state available in the recall notice at that date.
Who issued the recall?
A&P Creations LLC is conducting the recall with the knowledge of FDA. The company says it distributed biQ-FEL as a finished product and did not manufacture or formulate the product.
Consumers with recall questions can use the company contact information provided in the FDA-posted notice. For health effects, the notice separately directs consumers to their healthcare provider and FDA MedWatch.
Direct answer
The current FDA-posted recall covers biQ-FEL 500 mL lots biQ-f001-06-25 and biQ-003-01-26. Consumers with an affected bottle should stop using it immediately and are urged to destroy it.
FDA testing had already identified undeclared sildenafil and tadalafil in May. The September recall is the newer consumer-protection action that adds specific recalled lots, distribution information and direct stop-use instructions.
Verification note
ThePulseSignal reviewed FDA’s September recall notice and compared it with FDA’s May 27 public warning for biQ-FEL. The earlier notice establishes that the hidden sildenafil and tadalafil finding predates the recall; the September notice establishes the consumer-level recall, affected lots, distribution channels, stop-use instruction and no-adverse-events-reported state as of September 14.
Limitations and unresolved facts
The FDA-posted company announcement does not establish how many recalled bottles remain with consumers, how many were sold through each marketplace, or whether later adverse-event reports will emerge. TPS also does not infer an individual medical outcome from possession or use of the product. Later FDA recall classification, expanded lots, company remedy instructions or enforcement action should update this same canonical if the reader job remains the same.